Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan

Gupta, 2003, Emerging antibiotic resistance in urinary tract pathogens, Infect Dis Clin North Am, 17, 243, 10.1016/S0891-5520(03)00006-0 Falagas, 2008, Antimicrobial resistance of Esherichia coli urinary isolates from primary care patients in Greece, Med Sci Monit, 14, CR75 Paterson, 2005, Extended-spectrum β-lactamases: a clinical update, Clin Microbiol Rev, 18, 657, 10.1128/CMR.18.4.657-686.2005 Eschenburg, 2005, Evidence that the fosfomycin target Cys115 in UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) is essential for product release, J Biol Chem, 280, 3757, 10.1074/jbc.M411325200 Kahan, 1974, The mechanism of action of fosfomycin (phosphonomycin), Ann N Y Acad Sci, 235, 364, 10.1111/j.1749-6632.1974.tb43277.x Clinical and Laboratory Standards Institue, 2009 Garner, 1988, CDC definitions for nosocomial infections, 1988, Am J Infect Control, 16, 28, 10.1016/0196-6553(88)90053-3 Horan, 2008, CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting; 2008, Am J Infect Control, 36, 309, 10.1016/j.ajic.2008.03.002 Jean, 2002, Antimicrobial susceptibilities among cilinical isolates of extended-spectrum cephalosporin-resistant Gram-negative bacteria in a Taiwanese University Hospital, J Antimicrob Chemother, 49, 69, 10.1093/jac/49.1.69 Paterson, 2000, Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum β–lactamase production in Klebsiella pneumoniae isolates causing bacteremia, Clin Infect Dis, 30, 473, 10.1086/313719 Lautenbach, 2001, Epidemiology investigation of fluoroquinolone resistance in infections due to extended-spectrumβ–lactamase–producing Escherichia coli and Klebsiella pneumoniae, Clin Infect Dis, 33, 1288, 10.1086/322667 Liao, 2006, In vitro activities of 16 antimicrobial agents against clinical isolates of extended-spectrumβ–lactamase–producing Escherichia coli and Klebsiella pneumoniae in two regional hospitals in Taiwan, J Microbiol Immunol Infect, 39, 59 Hawser, 2009, In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005-2007: results from the SMART study, Int J Antimicrob Agents, 34, 585, 10.1016/j.ijantimicag.2009.07.013 Ko, 2007, In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum β-lactamase-producing Escherichia coli isolated from urine and blood, Diagn Microbiol Infect Dis, 58, 111, 10.1016/j.diagmicrobio.2006.11.015 de Cueto, 2006, In vitro activity of fosfomycin against extended-spectrum-β-lactamase producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures, Antimicrob Agents Chemother, 50, 368, 10.1128/AAC.50.1.368-370.2006 Canton, 2006, The CTX-M β-lactamase pandemic, Curr Opin Microbiol, 9, 466, 10.1016/j.mib.2006.08.011 Yu, 2002, Molecular epidemiology of extended-spectrum-β-lactamase–producing, fluoroquinolone-resistant isolates of Klebsiella pneumoniae in Taiwan, J Clin Microbiol, 40, 4666, 10.1128/JCM.40.12.4666-4669.2002 Yan, 2000, Dissemination of CTX-M-3 and CMY-2 β-lactamases among clinical isolates of Escherichia coli in southern Taiwan, J Clin Microbiol, 38, 4320, 10.1128/JCM.38.12.4320-4325.2000 Heffernan, 2009, Prevalence and types of extended-spectrum-β-lactamase among urinary Escherichia coli and Klebsiella spp. in New Zealand, Int J Antimicrob Agents, 34, 544, 10.1016/j.ijantimicag.2009.07.014 Prakash, 2009, Oral and parenteral therapeutic options for outpatient urinary infections caused by Enterobacteriaceae producing CTX-M extended-spectrum β-lactamases, Antimicrob Agents Chemother, 53, 1278, 10.1128/AAC.01519-08 Ho, 2007, Antimicrobial resistance in Escherichia coli outpatient urinary isolates from women: emerging multidrug resistance phenotypes, Diagn Microbiol Infect Dis, 59, 439, 10.1016/j.diagmicrobio.2007.06.012 Falagas, 2010, Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systematic review, Lancet Infect Dis, 10, 43, 10.1016/S1473-3099(09)70325-1 Falagas, 2008, Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin, Eur J Clin Microbiol Infect Dis, 27, 439, 10.1007/s10096-007-0456-4 Kashanian, 2008, Nitrofurantoin: the return of an old friend in the wake of growing resistance, BJU Int, 102, 1634, 10.1111/j.1464-410X.2008.07809.x Procop, 2003, Cross-class resistance to non-β-lactam antimicrobials in extended-spectrum β-lactamase-producing Klebsiella pneumoniae, Am J Clin Pathol, 120, 265, 10.1309/BWQKWB2WN6W5X1CC Melzer, 2007, Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli, J Infect, 55, 254